<DOC>
	<DOCNO>NCT02174848</DOCNO>
	<brief_summary>Patients PKAN treat iron chelator deferiprone 18 month . Only patient complete earlier study TIRCON2012V1 ( double-blind placebo-controlled trial participant randomize receive either deferiprone placebo 18 month ) eligible enroll .</brief_summary>
	<brief_title>Long-term Deferiprone Treatment Patients With Pantothenate Kinase-Associated Neurodegeneration</brief_title>
	<detailed_description>TIRCON2012V1-EXT multi-center , single-arm , open-label study . All patient complete earlier study TIRCON2012V1 eligible take part . In initial study , patient randomize 2:1 ratio receive 18 month treatment either iron chelator deferiprone placebo , respectively . In extension study , participant receive deferiprone 18 month . Thus , depend product receive earlier , patient deferiprone total either 1.5 year 3 year . As early study , assessment carry every six month look safety drug see patient show improvement dystonia symptom PKAN .</detailed_description>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Completed study TIRCON2012V1 Withdrew study TIRCON2012V1 reason safety Plan participate another clinical trial time day enrolment 30 day posttreatment current study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pantothenate Kinase-Associated Neurodegeneration</keyword>
	<keyword>PKAN</keyword>
	<keyword>Neurodegeneration Brain Iron Accumulation</keyword>
	<keyword>NBIA</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Ferriprox</keyword>
</DOC>